M
Martin T. King
Researcher at Brigham and Women's Hospital
Publications - 91
Citations - 1281
Martin T. King is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Prostate cancer & Brachytherapy. The author has an hindex of 12, co-authored 77 publications receiving 1037 citations. Previous affiliations of Martin T. King include Stanford University & Dana Corporation.
Papers
More filters
Journal ArticleDOI
Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV Infection
Sharon Walmsley,Barry Bernstein,Martin T. King,Jose R. Arribas,Gildon N. Beall,Peter Ruane,Margaret Johnson,David W. Johnson,Richard G. Lalonde,Anthony J. Japour,Scott C. Brun,Eugene Sun +11 more
TL;DR: For the initial treatment of HIV-infected adults, a combination regimen that includes lopinavir-ritonavir is well tolerated and has antiviral activity superior to that of a nelfinavIR-containing regimen.
Journal ArticleDOI
Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
Ben Y. Durkee,Yushen Qian,Erqi L. Pollom,Martin T. King,Sara A. Dudley,J. Shaffer,Daniel T. Chang,Iris C. Gibbs,Jeremy D. Goldhaber-Fiebert,Kathleen C. Horst +9 more
TL;DR: Deterministic sensitivity analysis showed that THP in patients with metastatic HER2-positive breast cancer is unlikely to be cost effective in the United States, and probabilistic sensitivity analysis predicted 0% chance of cost effectiveness at a willingness to pay of $100,000 per QALY gained.
Journal ArticleDOI
Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer
David D. Yang,Brandon A. Mahal,Vinayak Muralidhar,Michelle D. Nezolosky,Marie E. Vastola,Shelby A. Labe,Ninjin Boldbaatar,Martin T. King,Neil E. Martin,Peter F. Orio,Clair J. Beard,Karen E. Hoffman,Quoc-Dien Trinh,Daniel E. Spratt,Felix Y. Feng,Paul L. Nguyen +15 more
TL;DR: Nearly one in three patients with Gleason 3+4 FIR harbored disease of higher grade or stage than their biopsy and clinical examination suggest, and these patients would be poor candidates for active surveillance.
Journal ArticleDOI
Active Surveillance for Low-Risk Prostate Cancer in Black Patients.
Santino Butler,Vinayak Muralidhar,Janice Chavez,Zoe H. Fullerton,Aman Mahal,Michelle D. Nezolosky,Marie E. Vastola,Shuang G. Zhao,Anthony V. D'Amico,Robert T. Dess,Felix Y. Feng,Martin T. King,Kent W. Mouw,Daniel E. Spratt,Quoc-Dien Trinh,Paul L. Nguyen,Timothy R. Rebbeck,Brandon A. Mahal +17 more
TL;DR: The use of active surveillance or watchful waiting as a management strategy for low-risk prostate cancer increased in Blacks with Low-Risk Prostate Cancer between 2010 and 2015.
Journal ArticleDOI
Racial disparities in brachytherapy administration and survival in women with locally advanced cervical cancer.
Stephanie Alimena,David D. Yang,Alexander Melamed,Brandon A. Mahal,Michael J. Worley,Sarah Feldman,Sarah Feldman,Kevin M. Elias,Kevin M. Elias,Peter F. Orio,Peter F. Orio,Larissa J. Lee,Larissa J. Lee,Martin T. King,Martin T. King +14 more
TL;DR: Black women with locally advanced cervical cancer are less likely to receive brachytherapy, which mediates survival differences by race, andimproving access to brachyTherapy may improve overall survival.